NCT07030400Recruiting

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

H. Lee Moffitt Cancer Center and Research Institute

Start Date

7/17/2025

Completion Date

6/1/2028

Summary

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included. * Subjects must be able to read and speak English or Spanish at the 8th grade level. Exclusion Criteria: * Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

Interventions

DRUG

Bruton's tyrosine kinase inhibitor

DRUG

B-Cell Lymphoma 2 Protein Inhibitor

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)

Locations

Moffitt Cancer Center

Tampa, Florida 33612

United States